4D Molecular Therapeutics (FDMT) EPS (Weighted Average and Diluted): 2021-2025
Historic EPS (Weighted Average and Diluted) for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to -$1.01.
- 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) fell 27.85% to -$1.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.75, marking a year-over-year decrease of 31.58%. This contributed to the annual value of -$2.98 for FY2024, which is 15.50% down from last year.
- Per 4D Molecular Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$1.01 for Q3 2025, which was down 3.06% from -$0.98 recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.24 during Q3 2023, and its lowest value of -$1.01 during Q3 2025.
- In the last 3 years, 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.79 in 2024 and averaged -$0.77.
- In the last 5 years, 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) soared by 69.62% in 2023 and then tumbled by 229.17% in 2024.
- Quarterly analysis of 5 years shows 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.85 in 2021, then climbed by 1.18% to -$0.84 in 2022, then increased by 8.33% to -$0.77 in 2023, then decreased by 16.88% to -$0.90 in 2024, then decreased by 27.85% to -$1.01 in 2025.
- Its last three reported values are -$1.01 in Q3 2025, -$0.98 for Q2 2025, and -$0.86 during Q1 2025.